Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBIT Margin (2025 - 2026)

Kura Oncology has reported EBIT Margin over the past 2 years, most recently at 431.51% for Q1 2026.

  • Quarterly EBIT Margin rose 2710.0% to 431.51% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 28.59% through Mar 2026, changed N/A year-over-year, with the annual reading at 449.94% for FY2025, 9140.0% down from the prior year.
  • EBIT Margin was 431.51% for Q1 2026 at Kura Oncology, down from 1140.9% in the prior quarter.
  • Over five years, EBIT Margin peaked at 1140.9% in Q4 2025 and troughed at 458.61% in Q1 2025.